Solventum's stock plummeted 5.12% at the market open on Friday, marking a significant downward move for the healthcare supplier.

The decline came despite the company reporting strong fourth-quarter earnings and 2026 guidance that exceeded Wall Street expectations. According to analyst reports, investors were concerned about margins that came in below consensus, which was attributed to the ongoing enterprise resource planning transition as the company continues to operate independently after its spin-off from 3M in 2024.

Additionally, market participants showed dissatisfaction with the source of the earnings beat, as a lower-than-expected tax rate contributed to the upside. While underlying business fundamentals appear positive, the immediate market reaction focused on these margin and quality-of-earnings concerns.